Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Apr 11:rs.3.rs-4219764.
doi: 10.21203/rs.3.rs-4219764/v1.

Effect of Metronidazole on Concentrations of Vaginal Bacteria Associated with Risk of HIV Acquisition

D J Valint  1 , Tina L Fiedler  1 , Congzhou Liu  1 , Sujatha Srinivasan  1 , David N Fredricks  1   2
Affiliations

Effect of Metronidazole on Concentrations of Vaginal Bacteria Associated with Risk of HIV Acquisition

D J Valint et al. Res Sq. .

Update in

Abstract

Several bacterial vaginosis (BV)-associated bacteria have been associated with elevated risk of HIV acquisition, however susceptibility of these bacteria to antibiotics is poorly understood. Vaginal samples were collected from 22 persons daily for two weeks following BV diagnosis. Metronidazole treatment was prescribed for 5-7 days. Changes in bacterial concentrations were measured with taxon-specific 16S rRNA gene quantitative PCR (qPCR) assays. A culture-based antimicrobial assay confirmed presence of antibiotics in vaginal swab samples. Bacterial DNA concentrations decreased during antibiotic administration for all thirteen bacterial taxa tested. Comparison of bacterial DNA concentrations in samples before administration of antibiotics to samples taken on the last day of antimicrobial assay-confirmed antibiotic presence showed a 2.3-4.5 log10-fold decrease across all taxa. Concentrations were frequently reduced to the qPCR assay's limit of detection, suggesting eradication of bacteria. Mean clearance time varied across taxa (1.2-8.6 days), with several bacteria (e.g., Gemella asaccharolytica, Sneathia spp., Eggerthella-like sp.) taking >7 days to suppress. Metronidazole reduces quantities of bacterial taxa associated with increased HIV acquisition risk. Eradication of high-risk vaginal bacteria using metronidazole is one promising avenue for reducing HIV acquisition risk. A 5-7-day treatment course may not be sufficient to suppress all bacteria.

PubMed Disclaimer

Conflict of interest statement

D.N.F and T.L.F. receive a royalty from BD around detection ofvaginal bacterial for diagnosis of bacterial vaginosis.

Figures

Figure 1.
Figure 1.
Concentrations of 13 vaginal bacteria over time during metronidazole treatment for a representative treatment course in one person with BV.
Figure 2.
Figure 2.
Box plot displaying log-fold change in bacterial concentrations over course of antibiotic treatment for BV, for each of thirteen bacterial taxa. Total number of treatments in which a bacterial taxon appeared is indicated to the right of each bacterial taxon.
Figure 3.
Figure 3.
Bar graph showing decreases in concentrations of bacterial DNA from baseline (1 day prior to confirmed antibiotic presence, black bar) to the last day of confirmed antibiotic presence (white bar) for each taxon assayed. Number of treatment courses in which a given taxa was observed is noted above each respective bar. Statistical significance assessed by Student’s t-test.
Figure 4.
Figure 4.
Box plot (A) showing time to suppression for each bacterial taxon (total number of treatments in which a bacterial taxon appeared is indicated along base of x-axis); scatter plot (B) showing relationship between baseline bacterial concentration and time to suppression.
Figure 5.
Figure 5.
Box plot showing time to suppression between different bacterial taxa, split by method of antibiotic administration (total number of treatments in which a bacterial taxon appeared is indicated along base of x-axis).
See this image and copyright information in PMC

References

    1. Ahrens P, Andersen LO, Lilje B, Johannesen TB, Dahl EG, Baig S, Jensen JS, Falk L. Changes in the vaginal microbiota following antibiotic treatment for Mycoplasma genitalium, Chlamydia trachomatis and bacterial vaginosis. PLoS One. 2020. Jul 28;15(7):e0236036. Doi: 10.1371/journal.pone.0236036. - DOI - PMC - PubMed
    1. Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis. 2014. May;41(5):290–1. doi: 10.1097/OLQ.0000000000000123. - DOI - PubMed
    1. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983. Jan;74(1):14–22. doi: 10.1016/0002-9343(83)91112-9. - DOI - PubMed
    1. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung’u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015. May 19;42(5):965–76. doi: 10.1016/j.immuni.2015.04.019. - DOI - PMC - PubMed
    1. Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Liu R, Crawford ED, Castañeda GR, Nagelkerke N, Coburn B, Cohen CR, Kaul R. Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. J Clin Invest. 2022. Mar 15;132(6):e152930. doi: 10.1172/JCI152930. - DOI - PMC - PubMed

Publication types

LinkOut - more resources